Nektar Therapeutics Stock Discussion

$Nektar Therapeutics (NKTR.US)$
The completion of target enrollment in REZOLVE-AD Phase 2b trial represents a significant milestone for Nektar's rezpegaldesleukin program. The 396-patient study achieved enrollment in just 14 months, indicating strong interest from both physicians and patients. The trial's design is particularly robust with its multi-regional approach spanning Europe (67%), US (17%), Canada (11%) and Australia (5%).
The study's focus on treatment-naïve p...

$Nektar Therapeutics (NKTR.US)$ Reuters· just
Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Ad Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics (NKTR.US)$
For Nektar Therapeutics, with its modest market cap of $193.7M, these results could be transformative. The CAR-T therapy market is projected to grow significantly and NKTR-255's potential to enhance existing CAR-T treatments positions it well for partnerships or licensing deals. The data showing superior complete response rates compared to historical benchmarks could translate to significant market opportunity, especially given t...

$Nektar Therapeutics (NKTR.US)$
08/12/2024 - 01:00
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months
NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold...

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Positive
73% complete response rate at 6 months vs 50% for placebo
5.8-fold improvement in CD8+ CAR-T cell kinetics compared to placebo
Two patients converted from partial to complete response with NKTR-255
Results exceeded historical benchmark data of 41-44% comple...

$Nektar Therapeutics (NKTR.US)$ Nektar Therapeutics Announced NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients With Relapsed or Refractory Large B-cell Lymphoma At ASH Meeting; 73% Of NKTR-255 Treatment Group Vs 50% Of Placebo Group Achieved Complete Response At 6 Months
Nektar Therapeutics (NASDAQ:NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatme...

$Nektar Therapeutics (NKTR.US)$
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Nektar Therapeutics (NKTR) presented preclinical data for NKTR-422, a novel modified CSF protein, at the 2024 ACR conference. The drug demonstrated promising results in inflammation resolution and tissue repair across multiple preclinical models. NKTR-422functions by targeting anti-inflammatory tissue resident macrop...

$Nektar Therapeutics (NKTR.US)$
Target price $7

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Nov. 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and...

$Nektar Therapeutics (NKTR.US)$ common go to 1,50